Assessment	O
of	O
the	O
circulating	O
cell	O
-	O
free	O
DNA	O
marker	O
association	O
with	O
diagnosis	O
and	O
prognostic	O
prediction	O
in	O
patients	O
with	O
lymphoma	B-DS
:	O
a	O
single	O
-	O
center	O
experience	O

Circulating	O
cell	O
-	O
free	O
DNA	O
(	O
ccfDNA	O
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
the	O
clinical	O
characteristics	O
and	O
prognosis	O
of	O
cancer	B-DS
patients	O
.	O

Our	O
objective	O
was	O
to	O
assess	O
whether	O
the	O
concentration	O
and	O
integrity	O
index	O
of	O
ccfDNA	O
in	O
plasma	O
may	O
be	O
useful	O
for	O
diagnosing	O
and	O
monitoring	O
the	O
progression	O
of	O
patients	O
with	O
lymphoma	B-DS
.	O

We	O
included	O
plasma	O
samples	O
from	O
174	O
lymphoma	B-DS
patients	O
and	O
80	O
healthy	O
individuals	O
.	O

The	O
total	O
concentration	O
of	O
ccfDNA	O
was	O
determined	O
using	O
a	O
fluorometry	O
method	O
,	O
and	O
the	O
DNA	O
integrity	O
index	O
(	O
DII	O
),	O
which	O
is	O
the	O
ratio	O
of	O
longer	O
to	O
shorter	O
DNA	O
fragments	O
,	O
for	O
the	O
APP	B-GP
gene	O
was	O
detected	O
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
.	O

The	O
median	O
levels	O
of	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
in	O
patients	O
with	O
lymphoma	B-DS
were	O
significantly	O
higher	O
than	O
those	O
in	O
controls	O
(	O
both	O
P	O
<	O
0	O
.	O
0001	O
).	O

Increases	O
in	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
were	O
associated	O
with	O
advanced	O
stage	O
disease	O
,	O
elevated	O
lactate	B-GP
dehydrogenase	I-GP
levels	O
,	O
and	O
a	O
higher	O
prognosis	O
score	O
.	O

In	O
patients	O
with	O
diffuse	B-DS
large	I-DS
B	I-DS
cell	I-DS
lymphoma	I-DS
(	O
DLBCL	B-DS
),	O
high	O
levels	O
of	O
ccfDNA	O
(	O
both	O
concentration	O
and	O
the	O
DII	O
)	O
showed	O
an	O
inferior	O
2	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
(	O
P	O
=	O
0	O
.	O
001	O
;	O
P	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
).	O

Our	O
study	O
provides	O
quantitative	O
and	O
qualitative	O
evidence	O
in	O
favor	O
of	O
using	O
ccfDNA	O
analysis	O
in	O
lymphoma	B-DS
patients	O
for	O
diagnostic	O
and	O
prognostic	O
assessments	O
.	O

Introduction	O

Lymphoma	B-DS
,	O
which	O
is	O
a	O
common	O
cancer	B-DS
of	O
the	O
hematopoietic	O
system	O
,	O
represents	O
a	O
heterogeneous	O
collection	O
of	O
diseases	O
with	O
different	O
biological	O
characteristics	O
and	O
clinical	O
outcomes	O
.	O

In	O
China	O
,	O
more	O
than	O
80	O
,	O
000	O
new	O
cases	O
of	O
lymphoma	B-DS
and	O
an	O
estimated	O
52	O
,	O
000	O
deaths	O
attributed	O
to	O
lymphoma	B-DS
were	O
reported	O
in	O
2015	O
[	O
1	O
].	O

The	O
overall	O
survival	O
of	O
patients	O
with	O
lymphoma	B-DS
tends	O
to	O
be	O
poor	O
primarily	O
because	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
most	O
patients	O
are	O
already	O
in	O
the	O
late	O
stages	O
and	O
thus	O
lose	O
the	O
opportunity	O
for	O
timely	O
treatment	O
[	O
2	O
].	O

Therefore	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
a	O
noninvasive	O
tool	O
to	O
improve	O
the	O
diagnosis	O
and	O
prognostic	O
evaluation	O
of	O
lymphoma	B-DS
patients	O
.	O

Circulating	O
cell	O
-	O
free	O
DNA	O
(	O
ccfDNA	O
)	O
are	O
DNA	O
fragments	O
circulating	O
within	O
the	O
bloodstream	O
and	O
can	O
be	O
obtained	O
by	O
a	O
simple	O
blood	O
collection	O
.	O

Mendel	O
and	O
Metais	O
first	O
reported	O
the	O
existence	O
of	O
ccfDNA	O
in	O
1948	O
[	O
3	O
],	O
and	O
the	O
presence	O
of	O
ccfDNA	O
has	O
been	O
identified	O
in	O
inflammatory	B-DS
disease	I-DS
[	O
4	O
],	O
autoimmune	B-DS
disease	I-DS
[	O
5	O
],	O
trauma	O
[	O
6	O
],	O
and	O
myocardial	B-DS
infarction	I-DS
[	O
7	O
].	O

Recently	O
,	O
quantifying	O
ccfDNA	O
levels	O
has	O
been	O
proposed	O
as	O
a	O
potential	O
biomarker	O
to	O
detect	O
malignant	B-DS
tumors	I-DS
.	O

A	O
study	O
by	O
Leon	O
et	O
al	O
.	O
[	O
8	O
]	O
suggested	O
that	O
compared	O
with	O
that	O
of	O
healthy	O
individuals	O
,	O
the	O
concentration	O
of	O
ccfDNA	O
was	O
significantly	O
increased	O
in	O
cancer	B-DS
patients	O
;	O
furthermore	O
,	O
this	O
phenomenon	O
was	O
confirmed	O
by	O
other	O
studies	O
on	O
breast	B-DS
tumors	I-DS
[	O
9	O
],	O
colorectal	B-DS
cancer	I-DS
[	O
10	O
],	O
lung	B-DS
cancer	I-DS
[	O
11	O
],	O
and	O
other	O
cancer	B-DS
types	O
[	O
12	O
].	O

The	O
ccfDNA	O
released	O
into	O
the	O
bloodstream	O
is	O
thought	O
to	O
originate	O
from	O
either	O
passive	O
release	O
from	O
apoptotic	O
and	O
necrotic	O
cells	O
or	O
active	O
secretion	O
from	O
nucleated	O
cells	O
such	O
as	O
lymphocytes	O
.	O

Unlike	O
uniformly	O
truncated	O
DNA	O
released	O
from	O
apoptotic	O
cells	O
,	O
ccfDNA	O
released	O
from	O
necrotic	O
tumor	B-DS
cells	O
varies	O
in	O
size	O
,	O
which	O
may	O
lead	O
to	O
elevated	O
levels	O
of	O
long	O
fragments	O
of	O
DNA	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
malignant	O
diseases	O
[	O
13	O
].	O

Several	O
studies	O
have	O
demonstrated	O
that	O
compared	O
to	O
that	O
of	O
healthy	O
individuals	O
,	O
the	O
DNA	O
integrity	O
index	O
(	O
DII	O
),	O
which	O
is	O
calculated	O
as	O
the	O
ratio	O
of	O
longer	O
to	O
shorter	O
DNA	O
fragments	O
,	O
was	O
increased	O
in	O
patients	O
with	O
cancers	B-DS
[	O
14	O
–	O
16	O
].	O

Although	O
the	O
presence	O
of	O
ccfDNA	O
has	O
been	O
widely	O
studied	O
in	O
malignant	B-DS
tumors	I-DS
,	O
there	O
are	O
only	O
few	O
reports	O
regarding	O
ccfDNA	O
in	O
lymphoproliferative	B-DS
diseases	I-DS
.	O

It	O
has	O
been	O
hypothesized	O
that	O
ccfDNA	O
may	O
be	O
a	O
good	O
candidate	O
for	O
diagnosis	O
and	O
prognosis	O
of	O
lymphoma	B-DS
because	O
some	O
studies	O
have	O
shown	O
that	O
the	O
concentration	O
of	O
ccfDNA	O
could	O
be	O
a	O
diagnostic	O
and	O
predictive	O
biomarker	O
in	O
lymphoma	B-DS
patients	O
[	O
17	O
,	O
18	O
];	O
however	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
are	O
no	O
studies	O
that	O
have	O
investigated	O
the	O
predictive	O
value	O
of	O
ccfDNA	O
integrity	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
value	O
of	O
the	O
concentration	O
and	O
integrity	O
of	O
ccfDNA	O
in	O
diagnosing	O
lymphoma	B-DS
patients	O
and	O
analyzed	O
these	O
parameters	O
to	O
identify	O
associations	O
with	O
clinical	O
characteristics	O
and	O
prognosis	O
.	O

Materials	O
and	O
methods	O

Population	O

There	O
were	O
174	O
lymphoma	B-DS
patients	O
enrolled	O
in	O
this	O
study	O
.	O

Among	O
the	O
included	O
lymphoma	B-DS
cases	O
,	O
126	O
were	O
B	B-DS
cell	I-DS
non	I-DS
-	I-DS
Hodgkin	I-DS
lymphoma	I-DS
(	O
B	B-DS
-	I-DS
NHL	I-DS
),	O
with	O
diffuse	B-DS
large	I-DS
B	I-DS
cell	I-DS
lymphoma	I-DS
(	O
DLBCL	B-DS
,	O
n	O
=	O
98	O
)	O
as	O
the	O
most	O
common	O
subtype	O
.	O

There	O
were	O
18	O
,	O
9	O
,	O
and	O
21	O
patients	O
diagnosed	O
with	O
HL	B-DS
,	O
T	B-DS
cell	I-DS
non	I-DS
-	I-DS
HL	I-DS
(	O
T	B-DS
-	I-DS
NHL	I-DS
),	O
and	O
extranodal	B-DS
NK	I-DS
/	I-DS
T	I-DS
cell	I-DS
lymphoma	I-DS
(	O
NK	B-DS
/	I-DS
TCL	I-DS
),	O
respectively	O
.	O

The	O
diagnosis	O
of	O
all	O
patients	O
was	O
histologically	O
confirmed	O
.	O

Patient	O
samples	O
were	O
obtained	O
from	O
West	O
China	O
Hospital	O
of	O
Sichuan	O
University	O
between	O
September	O
2014	O
and	O
January	O
2016	O
.	O

Plasma	O
samples	O
were	O
collected	O
at	O
the	O
time	O
of	O
initial	O
diagnosis	O
.	O

The	O
median	O
follow	O
-	O
up	O
time	O
was	O
13	O
.	O
5	O
months	O
and	O
ranged	O
from	O
1	O
to	O
36	O
months	O
.	O

The	O
main	O
patient	O
characteristics	O
are	O
provided	O
in	O
Table	O
1	O
.	O
Table	O
1Main	O
characteristics	O
of	O
patients	O
included	O
in	O
the	O
studyTotalHLB	B-DS
-	I-DS
NHLT	I-DS
-	I-DS
NHLNK	I-DS
/	I-DS
TCLDLBCLOthers	I-DS
(	O
n	O
=	O
174	O
)(	O
n	O
=	O
18	O
)(	O
n	O
=	O
98	O
)(	O
n	O
=	O
28	O
)(	O
n	O
=	O
9	O
)(	O
n	O
=	O
21	O
)	O
Gender	O
Male107106117613	O
Female678371138Age	O
(	O
range	O
),	O
years	O
≤	O
60117156116718	O
>	O
60573371223Stage	O
I	O
–	O
IIA6924211114	O
IIB	O
–	O
IV10516561787B	O
-	O
symptoms	O
No916601429	O
Yes83123814712Bulky	O
disease	O
No153138426921	O
Yes21514200Lactate	O
dehydrogenase	O
Normal9694817814	O
Elevated789501117IPI	O
Low	O
(	O
0	O
or	O
1	O
)	O
56	O
–	O
39836	O
Intermediate	O
low	O
(	O
2	O
)	O
38	O
–	O
225110	O
Intermediate	O
high	O
(	O
3	O
)	O
27	O
–	O
13815	O
High	O
(	O
4	O
or	O
5	O
)	O
35	O
–	O
24740IPS	O
0	O
–	O
2	O
–	O
9	O
––––	O
≥	O
3	O
–	O
9	O
––––	O
Data	O
were	O
presented	O
as	O
n	O
HL	B-DS
,	O
Hodgkin	B-DS
’	I-DS
s	I-DS
lymphoma	I-DS
;	O
B	B-DS
-	I-DS
NHL	I-DS
,	O
B	B-DS
cell	I-DS
non	I-DS
-	I-DS
Hodgkin	I-DS
’	I-DS
s	I-DS
lymphoma	I-DS
;	O
DLBCL	B-DS
,	O
diffuse	B-DS
large	I-DS
B	I-DS
cell	I-DS
lymphoma	I-DS
;	O
Others	O
group	O
included	O
9	O
follicular	B-DS
lymphoma	I-DS
,	O
7	O
small	B-DS
cell	I-DS
lymphoma	I-DS
/	O
chronic	B-DS
lymphocytic	I-DS
leukemia	I-DS
,	O
6	O
marginal	B-DS
zone	I-DS
lymphoma	I-DS
,	O
5	O
mantle	B-DS
cell	I-DS
lymphoma	I-DS
and	O
1	O
Burkitt	B-DS
lymphoma	I-DS
;	O
T	B-DS
-	I-DS
NHL	I-DS
,	O
T	B-DS
cell	I-DS
non	I-DS
-	I-DS
Hodgkin	I-DS
’	I-DS
s	I-DS
lymphoma	I-DS
,	O
included	O
in	O
4	O
peripheral	B-DS
T	I-DS
cell	I-DS
lymphoma	I-DS
,	O
3	O
anaplastic	B-DS
large	I-DS
-	I-DS
cell	I-DS
lymphoma	I-DS
,	O
2	O
angioimmunoblastic	B-DS
T	I-DS
cell	I-DS
lymphoma	I-DS
;	O
NK	B-DS
/	I-DS
TCL	I-DS
,	O
extranodal	B-DS
NK	I-DS
/	I-DS
T	I-DS
cell	I-DS
lymphoma	I-DS
;	O
IPI	O
,	O
international	O
prognostic	O
index	O
;	O
IPS	O
,	O
international	O
prognostic	O
score	O

A	O
control	O
group	O
consisting	O
of	O
80	O
healthy	O
individuals	O
was	O
included	O
to	O
establish	O
the	O
normal	O
range	O
of	O
ccfDNA	O
levels	O
in	O
plasma	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
patients	O
and	O
controls	O
according	O
to	O
the	O
institutional	O
guidelines	O
,	O
and	O
the	O
study	O
was	O
approved	O
by	O
the	O
Human	O
Research	O
Ethics	O
Committee	O
of	O
the	O
West	O
China	O
Hospital	O
of	O
Sichuan	O
University	O
.	O

Sample	O
collection	O
and	O
DNA	O
extraction	O

Peripheral	O
blood	O
samples	O
were	O
collected	O
into	O
tubes	O
containing	O
EDTA	O
and	O
centrifuged	O
(	O
2000	O
×	O
g	O
,	O
10	O
min	O
,	O
4	O
°	O
C	O
)	O
within	O
4	O
h	O
of	O
collection	O
.	O

To	O
prevent	O
cellular	O
DNA	O
contamination	O
,	O
the	O
plasma	O
supernatants	O
were	O
carefully	O
removed	O
and	O
recentrifuged	O
(	O
16	O
,	O
000	O
×	O
g	O
;	O
10	O
min	O
at	O
4	O
°	O
C	O
).	O

The	O
prepared	O
plasma	O
samples	O
were	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
further	O
analysis	O
.	O

ccfDNA	O
was	O
extracted	O
using	O
the	O
MagMAX	O
™	O
Cell	O
-	O
Free	O
DNA	O
Isolation	O
Kit	O
(	O
Applied	O
Biosystems	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
following	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

The	O
isolated	O
ccfDNA	O
was	O
eluted	O
in	O
20	O
μl	O
of	O
the	O
provided	O
solution	O
and	O
stored	O
at	O
−	O
20	O
°	O
C	O
prior	O
to	O
quantitative	O
and	O
qualitative	O
analyses	O
.	O

Quantification	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O

Quantification	O
of	O
ccfDNA	O
was	O
performed	O
by	O
fluorometry	O
using	O
the	O
Qubit	O
®	O
dsDNA	O
HS	O
Assay	O
Kit	O
(	O
Molecular	O
Probes	O
,	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocols	O
,	O
and	O
the	O
plates	O
were	O
read	O
in	O
a	O
Qubit	O
®	O
3	O
.	O
0	O
fluorometer	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
).	O

The	O
ccfDNA	O
concentrations	O
were	O
determined	O
from	O
a	O
standard	O
curve	O
obtained	O
using	O
the	O
standard	O
stock	O
(	O
provided	O
by	O
the	O
manufacturer	O
).	O

Two	O
repeated	O
tests	O
were	O
performed	O
for	O
each	O
set	O
of	O
concentration	O
measurements	O
and	O
the	O
resulting	O
data	O
were	O
averaged	O
.	O

Real	O
-	O
time	O
quantitative	O
PCR	O
of	O
DNA	O
fragments	O

The	O
integrity	O
of	O
ccfDNA	O
in	O
plasma	O
was	O
determined	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

The	O
quantitative	O
assay	O
was	O
based	O
on	O
amplification	O
of	O
the	O
APP	B-GP
gene	O
(	O
amyloid	B-GP
beta	I-GP
precursor	I-GP
protein	I-GP
,	O
chromosome	O
21q21	O
.	O
3	O
,	O
accession	O
NM_000484	O
);	O
the	O
lengths	O
of	O
the	O
two	O
amplicons	O
were	O
67	O
and	O
180	O
bp	O
and	O
were	O
obtained	O
using	O
two	O
primer	O
pairs	O
as	O
reported	O
previously	O
[	O
19	O
].	O

The	O
primer	O
set	O
for	O
APP67	O
amplified	O
both	O
shorter	O
(	O
truncated	O
by	O
apoptosis	O
)	O
and	O
longer	O
DNA	O
fragments	O
(	O
truncated	O
by	O
nonapoptotic	O
means	O
),	O
whereas	O
the	O
APP180	O
amplified	O
only	O
the	O
longer	O
DNA	O
fragments	O
.	O

Quantification	O
of	O
ccfDNA	O
fragments	O
was	O
performed	O
using	O
the	O
CFX96	O
Touch	O
™	O
Real	O
-	O
Time	O
instrument	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
).	O

The	O
reaction	O
mixture	O
for	O
each	O
direct	O
quantitative	O
real	O
-	O
time	O
PCR	O
comprised	O
12	O
.	O
5	O
μl	O
of	O
SYBR	O
®	O
Premix	O
Ex	O
Taq	O
™	O
II	O
(	O
TaKaRa	O
,	O
Shiga	O
,	O
Japan	O
),	O
1	O
μl	O
(	O
0	O
.	O
4	O
μM	O
)	O
of	O
each	O
primer	O
,	O
and	O
2	O
μl	O
DNA	O
in	O
a	O
total	O
reaction	O
volume	O
of	O
20	O
μl	O
.	O

The	O
sequences	O
of	O
the	O
primers	O
are	O
as	O
follows	O
:	O
APP67	O
:	O
forward	O
,	O
5	O
′-	O
TCAGGTTGACGCCGCTGT	O
-	O
3	O
′	O
and	O
reverse	O
,	O
5	O
′-	O
TTCGTAGCCG	O
TTCTGCTGC	O
-	O
3	O
′;	O
and	O
APP180	O
:	O
forward	O
,	O
5	O
′-	O
TCAGGTTGACGCCGCTGT	O
-	O
3	O
′	O
and	O
reverse	O
,	O
5	O
′-	O
TCTATAAATGGACACCGATGGGTAGT	O
-	O
3	O
′.	O

The	O
real	O
-	O
time	O
PCR	O
protocol	O
included	O
an	O
initial	O
denaturation	O
step	O
at	O
95	O
°	O
C	O
for	O
30	O
s	O
followed	O
by	O
40	O
cycles	O
of	O
denaturation	O
at	O
95	O
°	O
C	O
for	O
5	O
s	O
and	O
annealing	O
at	O
64	O
°	O
C	O
for	O
30	O
s	O
.	O

A	O
melting	O
curve	O
analysis	O
was	O
conducted	O
to	O
confirm	O
PCR	O
product	O
specificity	O
,	O
and	O
the	O
DNA	O
copy	O
number	O
of	O
each	O
sample	O
was	O
determined	O
using	O
a	O
standard	O
curve	O
with	O
serial	O
dilutions	O
(	O
2	O
×	O
10	O
−	O
1	O
−	O
2	O
×	O
105	O
ng	O
/	O
ml	O
)	O
of	O
human	B-OG
genomic	O
DNA	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
;	O
200	O
μg	O
/	O
ml	O
).	O

All	O
samples	O
were	O
analyzed	O
in	O
duplicate	O
,	O
and	O
a	O
negative	O
control	O
(	O
without	O
template	O
)	O
was	O
included	O
in	O
each	O
plate	O
.	O

All	O
quantitative	O
real	O
-	O
time	O
PCR	O
assays	O
were	O
performed	O
in	O
a	O
blinded	O
fashion	O
without	O
knowledge	O
of	O
the	O
specimen	O
identity	O
.	O

Statistical	O
analysis	O

Comparison	O
of	O
the	O
relative	O
expression	O
levels	O
of	O
ccfDNA	O
(	O
including	O
concentration	O
and	O
the	O
DII	O
)	O
between	O
patients	O
and	O
controls	O
was	O
performed	O
by	O
applying	O
the	O
nonparametric	O
Mann	O
-	O
Whitney	O
test	O
.	O

Analysis	O
of	O
receiver	O
operating	O
characteristics	O
(	O
ROC	O
)	O
curves	O
and	O
binary	O
logistic	O
regression	O
were	O
performed	O
to	O
evaluate	O
the	O
diagnostic	O
performance	O
of	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
in	O
lymphoma	B-DS
.	O

The	O
relationship	O
between	O
the	O
levels	O
of	O
ccfDNA	O
and	O
the	O
clinicopathological	O
features	O
of	O
lymphoma	B-DS
patients	O
was	O
estimated	O
as	O
appropriate	O
per	O
variable	O
type	O
.	O

In	O
detail	O
,	O
differences	O
in	O
the	O
ccfDNA	O
levels	O
among	O
the	O
different	O
groups	O
of	O
categorical	O
parameters	O
were	O
analyzed	O
by	O
either	O
the	O
nonparametric	O
Mann	O
-	O
Whitney	O
test	O
for	O
binary	O
variables	O
or	O
the	O
respective	O
Kruskal	O
-	O
Wallis	O
test	O
for	O
the	O
parameters	O
consisting	O
of	O
several	O
independent	O
groups	O
.	O

The	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
approach	O
and	O
Cox	O
proportional	O
hazard	O
regression	O
analysis	O
were	O
used	O
to	O
determine	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
).	O

PFS	O
was	O
defined	O
as	O
the	O
time	O
from	O
initial	O
diagnosis	O
until	O
disease	O
progression	O
/	O
relapse	O
or	O
death	O
from	O
any	O
cause	O
.	O

A	O
two	O
-	O
sided	O
P	O
<	O
0	O
.	O
05	O
indicated	O
statistical	O
significance	O
.	O

All	O
analyses	O
were	O
performed	O
using	O
SPSS	O
software	O
version	O
22	O
.	O
0	O
(	O
IBM	O
Corp	O
.,	O
Armonk	O
,	O
NY	O
)	O
and	O
MedCalc	O
software	O
version	O
15	O
.	O
10	O
(	O
MedCalc	O
Software	O
,	O
Ostend	O
,	O
Belgium	O
).	O

Results	O

Concentration	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O
in	O
healthy	O
individuals	O
and	O
lymphoma	B-DS
patients	O

The	O
median	O
concentration	O
of	O
ccfDNA	O
in	O
the	O
80	O
healthy	O
individuals	O
tested	O
was	O
209	O
.	O
0	O
ng	O
/	O
ml	O
(	O
mean	O
222	O
.	O
5	O
ng	O
/	O
ml	O
,	O
range	O
100	O
.	O
0	O
–	O
456	O
.	O
0	O
ng	O
/	O
ml	O
);	O
however	O
,	O
in	O
patients	O
with	O
lymphoma	B-DS
(	O
n	O
=	O
174	O
),	O
this	O
concentration	O
was	O
significantly	O
higher	O
(	O
median	O
686	O
.	O
0	O
ng	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
with	O
greater	O
variability	O
among	O
the	O
patients	O
(	O
mean	O
1407	O
.	O
6	O
ng	O
/	O
ml	O
,	O
range	O
100	O
.	O
0	O
–	O
14	O
,	O
180	O
.	O
0	O
ng	O
/	O
ml	O
).	O

Elevated	O
ccfDNA	O
concentration	O
levels	O
were	O
observed	O
in	O
patients	O
with	O
HL	B-DS
(	O
n	O
=	O
18	O
,	O
median	O
681	O
.	O
0	O
ng	O
/	O
ml	O
,	O
mean	O
988	O
.	O
8	O
ng	O
/	O
ml	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
DLBCL	B-DS
(	O
n	O
=	O
98	O
,	O
median	O
845	O
.	O
0	O
ng	O
/	O
ml	O
,	O
mean	O
1722	O
.	O
2	O
ng	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
other	O
types	O
of	O
B	B-DS
-	I-DS
NHL	I-DS
(	O
n	O
=	O
28	O
,	O
median	O
332	O
.	O
0	O
ng	O
/	O
ml	O
,	O
mean	O
1096	O
.	O
3	O
ng	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
T	B-DS
-	I-DS
NHL	I-DS
(	O
n	O
=	O
9	O
,	O
median	O
942	O
.	O
0	O
ng	O
/	O
ml	O
,	O
mean	O
1247	O
.	O
0	O
ng	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
and	O
NK	B-DS
/	I-DS
TCL	I-DS
(	O
n	O
=	O
21	O
,	O
median	O
662	O
.	O
0	O
ng	O
/	O
ml	O
,	O
mean	O
782	O
.	O
7	O
ng	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
(	O
Fig	O
.	O
1a	O
).	O
Fig	O
.	O
1Circulating	O
cell	O
-	O
free	O
DNA	O
levels	O
in	O
the	O
plasma	O
of	O
lymphoma	B-DS
patients	O
.	O

Box	O
plots	O
showed	O
circulating	O
cell	O
-	O
free	O
DNA	O
levels	O
of	O
a	O
concentrations	O
and	O
b	O
DII	O
in	O
healthy	O
controls	O
and	O
patients	O
with	O
lymphoma	B-DS
,	O
presented	O
as	O
median	O
value	O
(	O
black	O
line	O
),	O
interquartile	O
range	O
(	O
box	O
),	O
and	O
5th	O
and	O
95th	O
percentiles	O
(	O
whiskers	O
)	O

To	O
assess	O
the	O
diagnostic	O
accuracy	O
of	O
the	O
ccfDNA	O
levels	O
in	O
lymphoma	B-DS
patients	O
,	O
an	O
ROC	O
curve	O
analysis	O
was	O
conducted	O
,	O
and	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
was	O
calculated	O
as	O
0	O
.	O
75	O
(	O
95	O
%	O
CI	O
0	O
.	O
66	O
–	O
0	O
.	O
84	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
for	O
HL	B-DS
,	O
0	O
.	O
86	O
(	O
95	O
%	O
CI	O
0	O
.	O
80	O
–	O
0	O
.	O
90	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
DLBCL	B-DS
,	O
and	O
0	O
.	O
79	O
(	O
95	O
%	O
CI	O
0	O
.	O
70	O
–	O
0	O
.	O
87	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
NK	B-DS
/	I-DS
TCL	I-DS
,	O
suggesting	O
a	O
moderate	O
discriminatory	O
power	O
.	O

For	O
HL	B-DS
,	O
the	O
sensitivity	O
and	O
specificity	O
were	O
61	O
and	O
100	O
%,	O
respectively	O
,	O
at	O
a	O
cut	O
-	O
off	O
of	O
456	O
.	O
0	O
ng	O
/	O
ml	O
;	O
for	O
DLBCL	B-DS
,	O
73	O
and	O
94	O
%	O
at	O
a	O
cut	O
-	O
off	O
of	O
340	O
.	O
0	O
ng	O
/	O
ml	O
,	O
and	O
for	O
NK	B-DS
/	I-DS
TCL	I-DS
,	O
71	O
and	O
96	O
%	O
at	O
a	O
cut	O
-	O
off	O
of	O
392	O
.	O
0	O
ng	O
/	O
ml	O
.	O

Based	O
on	O
these	O
results	O
,	O
elevated	O
levels	O
of	O
ccfDNA	O
were	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
lymphoma	B-DS
.	O

When	O
analyzed	O
as	O
a	O
logistic	O
regression	O
model	O
,	O
a	O
10	O
.	O
0	O
ng	O
/	O
ml	O
increase	O
in	O
the	O
ccfDNA	O
concentration	O
increased	O
the	O
lymphoma	B-DS
risk	O
by	O
7	O
.	O
3	O
%	O
(	O
odds	O
ratio	O
1	O
.	O
073	O
;	O
95	O
%	O
CI	O
1	O
.	O
045	O
–	O
1	O
.	O
102	O
).	O

Integrity	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O
in	O
healthy	O
individuals	O
and	O
lymphoma	B-DS
patients	O

The	O
DII	O
was	O
calculated	O
as	O
the	O
ratio	O
of	O
the	O
quantitative	O
real	O
-	O
time	O
PCR	O
results	O
using	O
the	O
two	O
primer	O
sets	O
as	O
follows	O
:	O
QAPP180	O
/	O
QAPP67	O
.	O

Because	O
the	O
annealing	O
sites	O
of	O
APP67	O
are	O
contained	O
within	O
the	O
APP180	O
annealing	O
sites	O
,	O
the	O
DII	O
would	O
be	O
1	O
.	O
0	O
when	O
the	O
template	O
DNA	O
was	O
not	O
truncated	O
and	O
0	O
.	O
0	O
when	O
all	O
of	O
the	O
template	O
DNA	O
was	O
truncated	O
into	O
fragments	O
smaller	O
than	O
180	O
bp	O
.	O

The	O
median	O
DII	O
in	O
patients	O
with	O
lymphoma	B-DS
was	O
0	O
.	O
39	O
(	O
mean	O
0	O
.	O
42	O
,	O
range	O
0	O
.	O
11	O
–	O
0	O
.	O
97	O
),	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
normal	O
control	O
subjects	O
(	O
median	O
0	O
.	O
21	O
,	O
mean	O
0	O
.	O
22	O
,	O
range	O
0	O
.	O
07	O
–	O
0	O
.	O
49	O
;	O
P	O
<	O
0	O
.	O
0001	O
).	O

Elevated	O
DII	O
values	O
were	O
observed	O
in	O
patients	O
with	O
HL	B-DS
(	O
median	O
0	O
.	O
37	O
,	O
mean	O
0	O
.	O
40	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
DLBCL	B-DS
(	O
median	O
0	O
.	O
43	O
,	O
mean	O
0	O
.	O
46	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
other	O
types	O
of	O
B	B-DS
-	I-DS
NHL	I-DS
(	O
median	O
0	O
.	O
34	O
,	O
mean	O
0	O
.	O
35	O
,	O
P	O
=	O
0	O
.	O
002	O
),	O
T	B-DS
-	I-DS
NHL	I-DS
(	O
median	O
0	O
.	O
42	O
,	O
mean	O
0	O
.	O
41	O
,	O
P	O
=	O
0	O
.	O
008	O
),	O
and	O
NK	B-DS
/	I-DS
TCL	I-DS
(	O
median	O
0	O
.	O
33	O
,	O
mean	O
0	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
respectively	O
(	O
Fig	O
.	O
1b	O
).	O

Using	O
the	O
ROC	O
analysis	O
,	O
the	O
AUC	O
of	O
the	O
ccfDNA	O
DII	O
was	O
0	O
.	O
83	O
(	O
95	O
%	O
CI	O
0	O
.	O
74	O
–	O
0	O
.	O
90	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
HL	B-DS
,	O
0	O
.	O
90	O
(	O
95	O
%	O
CI	O
0	O
.	O
83	O
–	O
0	O
.	O
93	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
DLBCL	B-DS
,	O
and	O
0	O
.	O
81	O
(	O
95	O
%	O
CI	O
0	O
.	O
72	O
–	O
0	O
.	O
88	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
NK	B-DS
/	I-DS
TCL	I-DS
.	O

Additionally	O
,	O
the	O
ROC	O
analysis	O
assessed	O
whether	O
a	O
combination	O
of	O
the	O
raw	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
could	O
improve	O
the	O
diagnostic	O
ability	O
compared	O
with	O
using	O
the	O
concentration	O
alone	O
.	O

The	O
results	O
showed	O
that	O
the	O
AUC	O
was	O
significantly	O
increased	O
after	O
the	O
addition	O
of	O
the	O
DII	O
to	O
the	O
ccfDNA	O
concentration	O
in	O
patients	O
with	O
DLBCL	B-DS
(	O
0	O
.	O
86	O
vs	O
.	O
0	O
.	O
91	O
;	O
Z	O
=	O
2	O
.	O
697	O
,	O
P	O
=	O
0	O
.	O
007	O
;	O
Fig	O
.	O
2	O
);	O
whereas	O
in	O
patients	O
with	O
either	O
HL	B-DS
or	O
NK	B-DS
/	I-DS
TCL	I-DS
,	O
there	O
was	O
only	O
a	O
trend	O
of	O
increased	O
AUC	O
observed	O
(	O
0	O
.	O
75	O
vs	O
.	O
0	O
.	O
84	O
;	O
Z	O
=	O
1	O
.	O
714	O
,	O
P	O
=	O
0	O
.	O
087	O
and	O
0	O
.	O
79	O
vs	O
.	O
0	O
.	O
88	O
;	O
Z	O
=	O
1	O
.	O
646	O
,	O
P	O
=	O
0	O
.	O
0997	O
,	O
respectively	O
).	O
Fig	O
.	O
2The	O
receiver	O
operating	O
characteristic	O
curves	O
of	O
the	O
circulating	O
cell	O
-	O
free	O
DNA	O
concentration	O
and	O
its	O
combination	O
with	O
DII	O
in	O
patients	O
with	O
DLBCL	B-DS
.	O

The	O
AUC	O
of	O
concentration	O
and	O
model	O
of	O
concentration	O
+	O
DII	O
was	O
0	O
.	O
86	O
(	O
95	O
%	O
CI	O
0	O
.	O
80	O
–	O
0	O
.	O
90	O
)	O
and	O
0	O
.	O
91	O
(	O
95	O
%	O
CI	O
0	O
.	O
86	O
–	O
0	O
.	O
95	O
),	O
respectively	O
(	O
Z	O
=	O
2	O
.	O
697	O
,	O
P	O
=	O
0	O
.	O
007	O
).	O

DII	O
,	O
DNA	O
integrity	O
index	O
;	O
AUC	O
,	O
area	O
under	O
the	O
curve	O

Correlation	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O
and	O
clinicopathological	O
features	O
in	O
lymphoma	B-DS
patients	O

To	O
assess	O
the	O
clinical	O
significance	O
of	O
ccfDNA	O
levels	O
,	O
we	O
analyzed	O
the	O
clinicopathological	O
correlations	O
in	O
the	O
total	O
lymphoma	B-DS
group	O
but	O
restricted	O
the	O
analysis	O
to	O
patients	O
with	O
DLBCL	B-DS
;	O
in	O
this	O
patient	O
subset	O
,	O
the	O
adverse	O
prognostic	O
factors	O
advanced	O
stage	O
disease	O
(	O
stage	O
IIB	O
–	O
IV	O
)	O
and	O
elevated	O
LDH	B-GP
levels	O
were	O
associated	O
with	O
increased	O
ccfDNA	O
levels	O
and	O
DII	O
(	O
Table	O
2	O
).	O

In	O
patients	O
with	O
DLBCL	B-DS
,	O
the	O
presence	O
of	O
B	O
-	O
symptoms	O
was	O
also	O
correlated	O
with	O
increases	O
in	O
both	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
.	O

As	O
a	O
consequence	O
,	O
patients	O
with	O
an	O
adverse	O
prognostic	O
score	O
had	O
higher	O
levels	O
of	O
ccfDNA	O
,	O
which	O
was	O
significant	O
among	O
all	O
lymphoma	B-DS
patients	O
and	O
DLBCL	B-DS
patients	O
[	O
20	O
,	O
21	O
].	O

Otherwise	O
,	O
no	O
statistical	O
significance	O
was	O
observed	O
when	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
were	O
analyzed	O
with	O
regard	O
to	O
other	O
clinical	O
parameters	O
such	O
as	O
age	O
,	O
gender	O
,	O
and	O
bulky	O
disease	O
.	O
Table	O
2Plasma	O
circulating	O
cell	O
-	O
free	O
DNA	O
levels	O
and	O
clinicopathologic	O
features	O
in	O
lymphoma	B-DS
patientsAll	O
patientsDLBCLConcentrationDIIConcentrationDIIGender	O
Male660	O
.	O
0	O
(	O
290	O
.	O
0	O
–	O
1684	O
.	O
0	O
)	O
0	O
.	O
38	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
54	O
)	O
764	O
.	O
0	O
(	O
352	O
.	O
0	O
–	O
1868	O
.	O
5	O
)	O
0	O
.	O
42	O
(	O
0	O
.	O
33	O
–	O
0	O
.	O
56	O
)	O
Female702	O
.	O
0	O
(	O
284	O
.	O
0	O
–	O
2000	O
.	O
0	O
)	O
0	O
.	O
42	O
(	O
0	O
.	O
33	O
–	O
0	O
.	O
53	O
)	O
1118	O
.	O
0	O
(	O
295	O
.	O
0	O
–	O
3080	O
.	O
0	O
)	O
0	O
.	O
48	O
(	O
0	O
.	O
35	O
–	O
0	O
.	O
59	O
)	O
P	O
0	O
.	O
7690	O
.	O
2340	O
.	O
5070	O
.	O
558Age	O
(	O
range	O
),	O
years	O
≤	O
60702	O
.	O
0	O
(	O
260	O
.	O
0	O
–	O
1868	O
.	O
5	O
)	O
0	O
.	O
39	O
(	O
0	O
.	O
31	O
–	O
0	O
.	O
53	O
)	O
802	O
.	O
0	O
(	O
287	O
.	O
0	O
–	O
2430	O
.	O
0	O
)	O
0	O
.	O
47	O
(	O
0	O
.	O
33	O
–	O
0	O
.	O
56	O
)	O
>	O
60656	O
.	O
0	O
(	O
355	O
.	O
0	O
–	O
1847	O
.	O
0	O
)	O
0	O
.	O
41	O
(	O
0	O
.	O
30	O
–	O
0	O
.	O
55	O
)	O
888	O
.	O
0	O
(	O
384	O
.	O
0	O
–	O
2220	O
.	O
0	O
)	O
0	O
.	O
43	O
(	O
0	O
.	O
34	O
–	O
0	O
.	O
58	O
)	O
P	O
0	O
.	O
4140	O
.	O
8560	O
.	O
6680	O
.	O
965Stage	O
I	O
–	O
IIA482	O
.	O
0	O
(	O
238	O
.	O
5	O
–	O
1081	O
.	O
0	O
)	O
0	O
.	O
34	O
(	O
0	O
.	O
28	O
–	O
0	O
.	O
47	O
)	O
488	O
.	O
0	O
(	O
262	O
.	O
8	O
–	O
1048	O
.	O
0	O
)	O
0	O
.	O
35	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
48	O
)	O
IIB	O
–	O
IV896	O
.	O
0	O
(	O
351	O
.	O
0	O
–	O
2330	O
.	O
0	O
)	O
0	O
.	O
43	O
(	O
0	O
.	O
34	O
–	O
0	O
.	O
56	O
)	O
1395	O
.	O
0	O
(	O
449	O
.	O
5	O
–	O
2720	O
.	O
0	O
)	O
0	O
.	O
52	O
(	O
0	O
.	O
41	O
–	O
0	O
.	O
62	O
)	O
P	O
0	O
.	O
003	O
0	O
.	O
0001	O
0	O
.	O
006	O
<	O
0	O
.	O
0001	O
B	O
-	O
symptoms	O
No496	O
.	O
0	O
(	O
267	O
.	O
0	O
–	O
1426	O
.	O
0	O
)	O
0	O
.	O
39	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
52	O
)	O
523	O
.	O
0	O
(	O
293	O
.	O
0	O
–	O
1672	O
.	O
8	O
)	O
0	O
.	O
41	O
(	O
0	O
.	O
31	O
–	O
0	O
.	O
54	O
)	O
Yes736	O
.	O
0	O
(	O
348	O
.	O
0	O
–	O
2240	O
.	O
0	O
)	O
0	O
.	O
41	O
(	O
0	O
.	O
32	O
–	O
0	O
.	O
54	O
)	O
1657	O
.	O
0	O
(	O
433	O
.	O
0	O
–	O
3520	O
.	O
0	O
)	O
0	O
.	O
52	O
(	O
0	O
.	O
39	O
–	O
0	O
.	O
63	O
)	O
P	O
0	O
.	O
1040	O
.	O
251	O
0	O
.	O
034	O
0	O
.	O
013	O
Bulky	O
disease	O
No662	O
.	O
0	O
(	O
287	O
.	O
0	O
–	O
1661	O
.	O
5	O
)	O
0	O
.	O
39	O
(	O
0	O
.	O
30	O
–	O
0	O
.	O
53	O
)	O
783	O
.	O
0	O
(	O
320	O
.	O
5	O
–	O
2330	O
.	O
0	O
)	O
0	O
.	O
43	O
(	O
0	O
.	O
34	O
–	O
0	O
.	O
55	O
)	O
Yes1011	O
.	O
0	O
(	O
269	O
.	O
0	O
–	O
2434	O
.	O
5	O
)	O
0	O
.	O
42	O
(	O
0	O
.	O
31	O
–	O
0	O
.	O
59	O
)	O
1148	O
.	O
0	O
(	O
334	O
.	O
5	O
–	O
2161	O
.	O
8	O
)	O
0	O
.	O
45	O
(	O
0	O
.	O
35	O
–	O
0	O
.	O
61	O
)	O
P	O
0	O
.	O
4310	O
.	O
4060	O
.	O
7410	O
.	O
737Lactate	O
dehydrogenase	O
Normal472	O
.	O
0	O
(	O
230	O
.	O
8	O
–	O
978	O
.	O
0	O
)	O
0	O
.	O
37	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
49	O
)	O
455	O
.	O
0	O
(	O
248	O
.	O
5	O
–	O
1114	O
.	O
0	O
)	O
0	O
.	O
39	O
(	O
0	O
.	O
30	O
–	O
0	O
.	O
52	O
)	O
Elevated1200	O
.	O
0	O
(	O
400	O
.	O
0	O
–	O
3020	O
.	O
0	O
)	O
0	O
.	O
43	O
(	O
0	O
.	O
33	O
–	O
0	O
.	O
59	O
)	O
1629	O
.	O
5	O
(	O
517	O
.	O
0	O
–	O
3520	O
.	O
0	O
)	O
0	O
.	O
52	O
(	O
0	O
.	O
38	O
–	O
0	O
.	O
63	O
)	O
P	O
<	O
0	O
.	O
0001	O
0	O
.	O
006	O
<	O
0	O
.	O
0001	O
0	O
.	O
003	O
Prognostic	O
score	O
Low	O
risk482	O
.	O
0	O
(	O
248	O
.	O
0	O
–	O
1024	O
.	O
0	O
)	O
0	O
.	O
37	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
51	O
)	O
522	O
.	O
0	O
(	O
267	O
.	O
5	O
–	O
1771	O
.	O
0	O
)	O
0	O
.	O
41	O
(	O
0	O
.	O
30	O
–	O
0	O
.	O
52	O
)	O
High	O
risk942	O
.	O
0	O
(	O
402	O
.	O
0	O
–	O
2600	O
.	O
0	O
)	O
0	O
.	O
42	O
(	O
0	O
.	O
34	O
–	O
0	O
.	O
57	O
)	O
1620	O
.	O
0	O
(	O
493	O
.	O
0	O
–	O
2870	O
.	O
0	O
)	O
0	O
.	O
52	O
(	O
0	O
.	O
39	O
–	O
0	O
.	O
66	O
)	O
P	O
0	O
.	O
001	O
0	O
.	O
01	O
0	O
.	O
002	O
0	O
.	O
005	O
Data	O
were	O
presented	O
as	O
median	O
(	O
IQR	O
25	O
–	O
75	O
);	O
IQR	O
,	O
interquartile	O
range	O
;	O
circulating	O
cell	O
-	O
free	O
DNA	O
analysis	O
included	O
in	O
concentration	O
and	O
DII	O
levels	O
;	O
DII	O
,	O
DNA	O
integrity	O
index	O
.	O

The	O
IPI	O
score	O
was	O
used	O
for	O
patients	O
with	O
non	B-DS
-	I-DS
Hodgkin	I-DS
’	I-DS
s	I-DS
lymphoma	I-DS
and	O
the	O
IPS	O
score	O
for	O
patients	O
with	O
Hodgkin	B-DS
’	I-DS
s	I-DS
lymphoma	I-DS
.	O

IPI	O
scores	O
0	O
and	O
1	O
were	O
considered	O
low	O
risk	O
,	O
2	O
and	O
3	O
as	O
high	O
risk	O
,	O
while	O
with	O
IPS	O
scores	O
0	O
–	O
2	O
were	O
considered	O
as	O
low	O
risk	O
and	O
3	O
as	O
high	O
risk	O
P	O
value	O
,	O
comparison	O
between	O
the	O
two	O
strata	O
of	O
each	O
individual	O
variable	O
.	O
P	O
values	O
below	O
0	O
.	O
05	O
were	O
shown	O
in	O
italics	O

Prognostic	O
significance	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O
in	O
diffuse	B-DS
large	I-DS
B	I-DS
cell	I-DS
lymphoma	I-DS
patients	O

The	O
role	O
of	O
the	O
ccfDNA	O
levels	O
at	O
the	O
time	O
of	O
diagnosis	O
as	O
a	O
prognostic	O
marker	O
was	O
analyzed	O
in	O
patients	O
with	O
DLBCL	B-DS
,	O
who	O
constituted	O
the	O
largest	O
diagnostic	O
entity	O
included	O
in	O
this	O
study	O
.	O

The	O
most	O
discriminatory	O
cut	O
-	O
offs	O
for	O
2	O
-	O
year	O
PFS	O
were	O
identified	O
by	O
ROC	O
.	O

The	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
were	O
analyzed	O
as	O
dichotomic	O
variables	O
using	O
1586	O
ng	O
/	O
ml	O
and	O
0	O
.	O
61	O
as	O
the	O
cut	O
-	O
off	O
points	O
,	O
respectively	O
.	O

As	O
shown	O
in	O
the	O
Kaplan	O
-	O
Meier	O
curves	O
for	O
the	O
different	O
levels	O
of	O
ccfDNA	O
concentration	O
,	O
patients	O
with	O
a	O
ccfDNA	O
concentration	O
>	O
1586	O
ng	O
/	O
ml	O
had	O
a	O
2	O
-	O
year	O
probability	O
of	O
PFS	O
of	O
only	O
44	O
%	O
(	O
95	O
%	O
CI	O
15	O
–	O
73	O
%),	O
whereas	O
patients	O
with	O
a	O
ccfDNA	O
concentration	O
≤	O
1586	O
ng	O
/	O
ml	O
had	O
significantly	O
higher	O
probability	O
of	O
2	O
-	O
year	O
PFS	O
at	O
78	O
%	O
(	O
95	O
%	O
CI	O
55	O
–	O
99	O
%;	O
P	O
=	O
0	O
.	O
001	O
;	O
Fig	O
.	O
3a	O
).	O

The	O
prognostic	O
value	O
of	O
ccfDNA	O
fragmentation	O
on	O
PFS	O
was	O
also	O
evaluated	O
using	O
the	O
DII	O
.	O

Patients	O
showing	O
a	O
DII	O
>	O
0	O
.	O
61	O
had	O
a	O
59	O
%	O
probability	O
of	O
2	O
-	O
year	O
PFS	O
(	O
95	O
%	O
CI	O
38	O
–	O
79	O
%),	O
which	O
was	O
significantly	O
shorter	O
than	O
that	O
in	O
patients	O
with	O
a	O
DII	O
≤	O
0	O
.	O
61	O
(	O
87	O
%,	O
95	O
%	O
CI	O
69	O
–	O
100	O
%,	O
P	O
<	O
0	O
.	O
0001	O
;	O
Fig	O
.	O
3b	O
).	O
Fig	O
.	O
3Survival	O
curves	O
of	O
DLBCL	B-DS
patients	O
stratified	O
by	O
circulating	O
cell	O
-	O
free	O
DNA	O
levels	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curve	O
and	O
log	O
-	O
rank	O
test	O
according	O
to	O
a	O
concentration	O
and	O
b	O
DII	O
determined	O
by	O
ccfDNA	O
analysis	O
were	O
using	O
the	O
cut	O
-	O
offs	O
identified	O
by	O
means	O
of	O
ROC	O
for	O
2	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
P	O
value	O
noted	O
in	O
the	O
figure	O
).	O

ccfDNA	O
,	O
circulating	O
cell	O
-	O
free	O
DNA	O
;	O
DII	O
,	O
DNA	O
integrity	O
index	O
;	O
ROC	O
,	O
receiver	O
operating	O
characteristic	O

Following	O
the	O
univariate	O
analysis	O
,	O
we	O
found	O
that	O
both	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
were	O
associated	O
with	O
PFS	O
;	O
moreover	O
,	O
advanced	O
stage	O
,	O
B	O
-	O
symptoms	O
,	O
and	O
elevated	O
LDH	B-GP
levels	O
were	O
significant	O
adverse	O
factors	O
(	O
Table	O
3	O
).	O

Thus	O
,	O
these	O
variables	O
were	O
assessed	O
in	O
a	O
multivariate	O
Cox	O
regression	O
model	O
,	O
which	O
showed	O
that	O
the	O
DII	O
appeared	O
to	O
be	O
a	O
statistically	O
independent	O
prognostic	O
factor	O
(	O
HR	O
=	O
3	O
.	O
04	O
,	O
95	O
%	O
CI	O
1	O
.	O
197	O
–	O
7	O
.	O
696	O
;	O
P	O
=	O
0	O
.	O
019	O
),	O
whereas	O
the	O
ccfDNA	O
concentration	O
was	O
not	O
significant	O
in	O
this	O
multivariate	O
analysis	O
(	O
HR	O
=	O
1	O
.	O
45	O
,	O
95	O
%	O
CI	O
0	O
.	O
490	O
–	O
4	O
.	O
263	O
;	O
P	O
=	O
0	O
.	O
504	O
).	O
Table	O
3Univariable	O
Cox	O
regression	O
models	O
for	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
in	O
diffuse	B-DS
large	I-DS
B	I-DS
cell	I-DS
lymphoma	I-DS
patientsHR	O
(	O
95	O
%	O
CI	O
)	O
P	O
valueGender	O
(	O
male	O
)	O
1	O
.	O
128	O
(	O
0	O
.	O
454	O
–	O
2	O
.	O
799	O
)	O
0	O
.	O
796Age	O
(>	O
60	O
years	O
)	O
1	O
.	O
196	O
(	O
0	O
.	O
495	O
–	O
2	O
.	O
886	O
)	O
0	O
.	O
692Advanced	O
stage7	O
.	O
977	O
(	O
1	O
.	O
856	O
–	O
34	O
.	O
29	O
)	O
0	O
.	O
005	O
B	O
-	O
symptoms6	O
.	O
639	O
(	O
2	O
.	O
404	O
–	O
18	O
.	O
33	O
)	O
<	O
0	O
.	O
0001	O
Bulky	O
disease0	O
.	O
571	O
(	O
0	O
.	O
133	O
–	O
2	O
.	O
456	O
)	O
0	O
.	O
452Elevated	O
LDH4	B-GP
.	O
545	O
(	O
1	O
.	O
522	O
–	O
13	O
.	O
57	O
)	O
0	O
.	O
007	O
Elevated	O
ccfDNA	O
Concentration4	O
.	O
270	O
(	O
1	O
.	O
653	O
–	O
11	O
.	O
03	O
)	O
0	O
.	O
003	O
DII5	O
.	O
165	O
(	O
2	O
.	O
187	O
–	O
12	O
.	O
19	O
)	O
<	O
0	O
.	O
0001	O
Data	O
were	O
presented	O
as	O
HR	O
(	O
95	O
%	O
CI	O
);	O
HR	O
,	O
hazard	O
ratio	O
;	O
CI	O
,	O
confidence	O
interval	O
.	O

ccfDNA	O
,	O
circulating	O
cell	O
-	O
free	O
DNA	O
;	O
elevated	O
ccfDNA	O
was	O
included	O
in	O
both	O
concentration	O
and	O
DII	O
levels	O
P	O
values	O
below	O
0	O
.	O
05	O
were	O
shown	O
in	O
italics	O

Discussion	O

This	O
study	O
reveals	O
that	O
compared	O
to	O
healthy	O
individuals	O
,	O
patients	O
with	O
lymphoma	B-DS
frequently	O
have	O
higher	O
concentrations	O
and	O
longer	O
strands	O
of	O
ccfDNA	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
which	O
correlates	O
with	O
clinical	O
parameters	O
and	O
was	O
demonstrated	O
to	O
be	O
a	O
negative	O
predictor	O
of	O
DLBCL	B-DS
patients	O
’	O
outcome	O
.	O

Recently	O
,	O
studies	O
conducted	O
in	O
various	O
malignancies	O
have	O
shown	O
that	O
ccfDNA	O
levels	O
are	O
significantly	O
increased	O
in	O
cancer	B-DS
[	O
22	O
,	O
23	O
].	O

Our	O
work	O
revealed	O
that	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
levels	O
were	O
elevated	O
in	O
patients	O
with	O
lymphoma	B-DS
.	O

The	O
analysis	O
of	O
the	O
histological	O
subsets	O
revealed	O
that	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
levels	O
varied	O
according	O
to	O
the	O
lymphoma	B-DS
subtype	O
.	O

Unfortunately	O
,	O
the	O
B	B-DS
-	I-DS
NHL	I-DS
and	O
T	B-DS
-	I-DS
NHL	I-DS
cohorts	O
were	O
insufficient	O
to	O
perform	O
a	O
significant	O
histological	O
subtype	O
analysis	O
.	O

There	O
are	O
only	O
few	O
reports	O
that	O
studied	O
the	O
clinical	O
impact	O
of	O
ccfDNA	O
levels	O
on	O
lymphoma	B-DS
patients	O
and	O
were	O
mainly	O
oriented	O
to	O
analyze	O
the	O
correlation	O
between	O
an	O
increase	O
in	O
the	O
ccfDNA	O
concentration	O
with	O
disease	O
risk	O
and	O
adverse	O
clinical	O
performance	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
other	O
analytical	O
parameters	O
exhibited	O
by	O
ccfDNA	O
such	O
as	O
the	O
DII	O
have	O
not	O
been	O
studied	O
in	O
lymphoma	B-DS
patients	O
.	O

Here	O
,	O
we	O
confirmed	O
the	O
usefulness	O
of	O
detecting	O
the	O
quantity	O
and	O
quality	O
of	O
ccfDNA	O
as	O
a	O
diagnostic	O
tool	O
for	O
lymphoma	B-DS
.	O

Data	O
from	O
our	O
ROC	O
analysis	O
showed	O
that	O
the	O
AUC	O
of	O
the	O
concentration	O
to	O
distinguish	O
HL	B-DS
,	O
DLBCL	B-DS
,	O
and	O
NK	B-DS
/	I-DS
TCL	I-DS
patients	O
from	O
normal	O
controls	O
was	O
0	O
.	O
75	O
,	O
0	O
.	O
86	O
,	O
and	O
0	O
.	O
79	O
,	O
respectively	O
;	O
furthermore	O
,	O
the	O
AUC	O
of	O
the	O
DII	O
was	O
higher	O
than	O
that	O
of	O
the	O
concentration	O
(	O
0	O
.	O
83	O
,	O
0	O
.	O
90	O
,	O
and	O
0	O
.	O
81	O
for	O
HL	B-DS
,	O
DLBCL	B-DS
,	O
and	O
NK	B-DS
/	I-DS
TCL	I-DS
,	O
respectively	O
),	O
indicating	O
that	O
the	O
ccfDNA	O
concentration	O
alone	O
appeared	O
to	O
be	O
insufficient	O
for	O
a	O
high	O
-	O
quality	O
diagnostic	O
performance	O
.	O

Hohaus	O
et	O
al	O
.	O
[	O
17	O
]	O
conducted	O
a	O
diagnostic	O
analysis	O
of	O
the	O
ccfDNA	O
concentration	O
for	O
patients	O
with	O
HL	B-DS
and	O
DLBCL	B-DS
and	O
found	O
that	O
the	O
maximum	O
sensitivity	O
and	O
specificity	O
did	O
not	O
exceed	O
75	O
%,	O
making	O
this	O
parameter	O
an	O
unlikely	O
candidate	O
for	O
lymphoma	B-DS
screening	O
.	O

Our	O
study	O
found	O
that	O
for	O
DLBCL	B-DS
patients	O
,	O
there	O
was	O
an	O
added	O
incremental	O
diagnostic	O
value	O
when	O
the	O
ccfDNA	O
concentration	O
was	O
combined	O
with	O
the	O
DII	O
.	O

Regarding	O
the	O
clinical	O
correlation	O
of	O
ccfDNA	O
levels	O
in	O
lymphoma	B-DS
patients	O
,	O
we	O
observed	O
an	O
association	O
between	O
the	O
ccfDNA	O
levels	O
and	O
a	O
number	O
of	O
clinical	O
parameters	O
that	O
indicate	O
a	O
worse	O
prognosis	O
such	O
as	O
advanced	O
stage	O
disease	O
,	O
the	O
presence	O
of	O
B	O
-	O
symptoms	O
,	O
elevated	O
LDH	B-GP
levels	O
,	O
and	O
high	O
IPI	O
score	O
;	O
these	O
correlations	O
suggest	O
that	O
both	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
might	O
reflect	O
actively	O
proliferating	O
disease	O
and	O
lymphoma	B-DS
burden	O
.	O

Nevertheless	O
,	O
a	O
literature	O
analysis	O
highlights	O
the	O
confusion	O
regarding	O
these	O
ccfDNA	O
parameters	O
with	O
tumor	B-DS
burden	O
and	O
predicting	O
a	O
therapeutic	O
response	O
.	O

Hohaus	O
et	O
al	O
.	O
[	O
17	O
]	O
also	O
observed	O
significant	O
associations	O
between	O
the	O
ccfDNA	O
concentration	O
and	O
some	O
adverse	O
parameters	O
,	O
whereas	O
a	O
study	O
by	O
Jones	O
et	O
al	O
.	O
[	O
18	O
]	O
found	O
that	O
the	O
ccfDNA	O
concentration	O
was	O
not	O
indicative	O
of	O
lymphoma	B-DS
burden	O
once	O
therapy	O
had	O
commenced	O
;	O
they	O
reported	O
that	O
only	O
lymphoma	B-DS
-	O
specific	O
DNA	O
such	O
as	O
Epstein	B-OG
-	I-OG
Barr	I-OG
virus	I-OG
DNA	O
could	O
be	O
used	O
to	O
monitor	O
the	O
disease	O
response	O
in	O
lymphoma	B-DS
patients	O
.	O

In	O
addition	O
,	O
both	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
were	O
not	O
significantly	O
different	O
between	O
germinal	O
center	O
B	O
cell	O
type	O
and	O
non	O
-	O
germinal	O
center	O
B	O
cell	O
type	O
DLBCL	B-DS
based	O
on	O
the	O
Hans	O
classification	O
system	O
(	O
data	O
not	O
shown	O
).	O

We	O
assessed	O
the	O
prognostic	O
significance	O
of	O
ccfDNA	O
levels	O
in	O
patients	O
with	O
DLBCL	B-DS
.	O

Our	O
data	O
showed	O
that	O
high	O
concentrations	O
of	O
ccfDNA	O
and	O
an	O
elevated	O
DII	O
were	O
strongly	O
correlated	O
with	O
poor	O
outcome	O
in	O
patients	O
with	O
DLBCL	B-DS
,	O
which	O
has	O
already	O
been	O
reported	O
[	O
17	O
].	O

However	O
,	O
our	O
study	O
data	O
revealed	O
that	O
the	O
ccfDNA	O
concentration	O
was	O
insufficient	O
as	O
an	O
independent	O
prognostic	O
factor	O
compared	O
to	O
other	O
existing	O
and	O
validated	O
adverse	O
factors	O
such	O
as	O
disease	O
stage	O
or	O
elevated	O
LDH	B-GP
levels	O
[	O
24	O
].	O

The	O
origin	O
of	O
ccfDNA	O
is	O
still	O
unclear	O
.	O

In	O
healthy	O
individuals	O
,	O
the	O
ccfDNA	O
concentration	O
is	O
low	O
,	O
which	O
is	O
ascribed	O
to	O
the	O
efficient	O
removal	O
of	O
most	O
nonliving	O
cells	O
from	O
circulation	O
by	O
phagocytes	O
.	O

Schwarzenbach	O
et	O
al	O
.	O
[	O
25	O
]	O
proposed	O
that	O
ccfDNA	O
could	O
be	O
released	O
by	O
either	O
apoptosis	O
or	O
necrosis	O
and	O
found	O
that	O
the	O
predominant	O
fragment	O
length	O
of	O
ccfDNA	O
frequently	O
occurred	O
in	O
multiples	O
of	O
180	O
bp	O
,	O
which	O
is	O
typical	O
of	O
DNA	O
released	O
from	O
apoptotic	O
cells	O
.	O

However	O
,	O
the	O
presence	O
of	O
larger	O
fragments	O
such	O
as	O
those	O
found	O
in	O
cancer	B-DS
patients	O
suggested	O
that	O
ccfDNA	O
could	O
also	O
be	O
derived	O
from	O
necrotic	O
cells	O
.	O

Moreover	O
,	O
some	O
studies	O
have	O
attributed	O
a	O
notable	O
fraction	O
of	O
ccfDNA	O
to	O
active	O
release	O
from	O
lymphocytes	O
[	O
26	O
].	O

ccfDNA	O
is	O
not	O
specific	O
to	O
neoplastic	O
conditions	O
as	O
increased	O
levels	O
have	O
also	O
been	O
identified	O
in	O
inflammatory	O
and	O
autoimmune	B-DS
diseases	I-DS
.	O

An	O
association	O
between	O
a	O
high	O
concentration	O
of	O
ccfDNA	O
and	O
poor	O
prognosis	O
may	O
be	O
linked	O
to	O
tumor	B-DS
burden	O
[	O
27	O
];	O
however	O
,	O
changes	O
in	O
the	O
total	O
ccfDNA	O
concentration	O
may	O
reflect	O
not	O
only	O
changes	O
in	O
circulating	O
tumor	B-DS
DNA	O
(	O
ctDNA	O
)	O
but	O
also	O
in	O
other	O
conditions	O
that	O
may	O
lead	O
to	O
an	O
increase	O
in	O
ccfDNA	O
,	O
including	O
infection	B-DS
or	O
chemotherapy	O
drug	O
-	O
induced	O
release	O
of	O
normal	O
ccfDNA	O
into	O
the	O
circulation	O
.	O

ctDNA	O
is	O
a	O
specific	O
ccfDNA	O
released	O
by	O
tumor	B-DS
cells	O
,	O
which	O
contains	O
genetic	O
and	O
epigenetic	O
alterations	O
concordant	O
with	O
those	O
of	O
the	O
primary	O
tumor	B-DS
.	O

This	O
may	O
explain	O
why	O
our	O
data	O
showed	O
the	O
levels	O
of	O
ccfDNA	O
in	O
HL	B-DS
patients	O
were	O
as	O
high	O
as	O
in	O
NHL	B-DS
patients	O
and	O
indicated	O
that	O
the	O
overall	O
concentration	O
of	O
ccfDNA	O
was	O
not	O
an	O
independent	O
significant	O
prognostic	O
factor	O
of	O
survival	O
to	O
some	O
extent	O
.	O

Actually	O
,	O
our	O
results	O
showed	O
the	O
limitations	O
of	O
analyzing	O
only	O
the	O
total	O
ccfDNA	O
levels	O
,	O
as	O
focusing	O
on	O
tumor	B-DS
-	O
specific	O
ccfDNA	O
might	O
serve	O
as	O
a	O
more	O
adequate	O
surrogate	O
biomarker	O
.	O

For	O
solid	B-DS
tumors	I-DS
,	O
many	O
studies	O
have	O
validated	O
that	O
genetic	O
alterations	O
detected	O
in	O
ctDNA	O
correspond	O
to	O
the	O
primary	O
tumor	B-DS
and	O
that	O
the	O
levels	O
of	O
ctDNA	O
could	O
assess	O
the	O
tumor	B-DS
response	O
and	O
even	O
provide	O
an	O
earlier	O
indication	O
of	O
disease	O
progression	O
[	O
28	O
–	O
30	O
].	O

Roschewski	O
et	O
al	O
.	O
[	O
31	O
]	O
reported	O
that	O
monitoring	O
ctDNA	O
could	O
identify	O
patients	O
with	O
DLBCL	B-DS
who	O
are	O
at	O
risk	O
of	O
recurrence	O
before	O
the	O
manifestation	O
of	O
clinical	O
evidence	O
of	O
disease	O
,	O
and	O
interim	O
ctDNA	O
may	O
be	O
a	O
promising	O
biomarker	O
to	O
identify	O
patients	O
at	O
high	O
risk	O
of	O
treatment	O
failure	O
.	O

However	O
,	O
additional	O
studies	O
on	O
ctDNA	O
are	O
required	O
to	O
prove	O
its	O
value	O
in	O
clinical	O
practice	O
.	O

Thus	O
,	O
as	O
the	O
ccfDNA	O
levels	O
could	O
still	O
reflect	O
disease	O
progression	O
[	O
32	O
],	O
they	O
remain	O
a	O
useful	O
biomarker	O
to	O
monitor	O
disease	O
status	O
,	O
especially	O
when	O
combined	O
with	O
other	O
parameters	O
such	O
as	O
the	O
DII	O
or	O
ctDNA	O
levels	O
.	O

In	O
this	O
study	O
,	O
it	O
should	O
be	O
noted	O
that	O
ccfDNA	O
extraction	O
was	O
performed	O
using	O
the	O
magnetic	O
bead	O
method	O
,	O
which	O
is	O
based	O
on	O
the	O
principle	O
of	O
nucleic	O
acid	O
adsorption	O
and	O
release	O
via	O
magnetic	O
beads	O
.	O

The	O
most	O
commonly	O
used	O
DNA	O
extraction	O
methods	O
include	O
the	O
phenol	O
-	O
chloroform	O
method	O
,	O
sodium	O
iodide	O
method	O
,	O
and	O
magnetic	O
bead	O
method	O
as	O
well	O
as	O
the	O
use	O
of	O
commercial	O
DNA	O
isolation	O
kits	O
[	O
33	O
].	O

Pan	O
et	O
al	O
.	O
[	O
34	O
]	O
compared	O
the	O
phenol	O
-	O
chloroform	O
method	O
,	O
commercial	O
kits	O
,	O
and	O
magnetic	O
bead	O
method	O
in	O
the	O
detection	O
of	O
mycobacterium	B-OG
tuberculosis	I-OG
DNA	O
and	O
found	O
that	O
the	O
magnetic	O
bead	O
method	O
had	O
the	O
highest	O
DNA	O
extraction	O
efficiency	O
and	O
the	O
best	O
reproducibility	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
demonstrated	O
that	O
the	O
quantification	O
and	O
integrity	O
analysis	O
of	O
ccfDNA	O
from	O
the	O
plasma	O
of	O
patients	O
with	O
lymphoma	B-DS
might	O
be	O
a	O
useful	O
noninvasive	O
technique	O
for	O
clinical	O
practice	O
.	O

In	O
patients	O
with	O
DLBCL	B-DS
,	O
high	O
levels	O
of	O
ccfDNA	O
and	O
an	O
elevated	O
integrity	O
index	O
were	O
associated	O
with	O
poor	O
prognosis	O
,	O
although	O
,	O
based	O
on	O
our	O
results	O
,	O
only	O
the	O
DII	O
was	O
an	O
independent	O
adverse	O
factor	O
for	O
PFS	O
.	O

These	O
results	O
suggest	O
that	O
additional	O
prospective	O
studies	O
with	O
larger	O
cohorts	O
and	O
a	O
longer	O
follow	O
-	O
up	O
should	O
be	O
initiated	O
to	O
assess	O
the	O
utility	O
of	O
ccfDNA	O
analysis	O
,	O
especially	O
using	O
tumor	B-DS
-	O
specific	O
ccfDNA	O
.	O

